Gilead Sciences's competition from AbbVie and Merck is just one of the reasons.
After a solid two-year run, Gilead Sciences (GILD -1.15%) has fallen from investors graces, down for the year. The biotech has become increasingly reliant on its hepatitis C drug Sovaldi, with competition from AbbVie (ABBV 0.25%)and Merck (MRK -0.11%) around the corner.
In the slideshow below, you'll find three reasons investors are down on Gilead Sciences and thoughts on the biotech's future.
Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
